Rep. Lloyd Doggett Purchases Shares of Johnson & Johnson (NYSE:JNJ)

Representative Lloyd Doggett (Democratic-Texas) recently bought shares of Johnson & Johnson (NYSE:JNJ). In a filing disclosed on October 5th, the Representative disclosed that they had bought between $1,001 and $15,000 in Johnson & Johnson stock on September 8th.

Representative Lloyd Doggett also recently made the following trade(s):

• Purchased $1,001 – $15,000 in shares of Home Depot (NYSE:HD) on 9/17/2026.
• Purchased $1,001 – $15,000 in shares of PPG Industries (NYSE:PPG) on 9/11/2026.
• Purchased $1,001 – $15,000 in shares of International Business Machines (NYSE:IBM) on 9/10/2026.
• Purchased $1,001 – $15,000 in shares of Procter & Gamble (NYSE:PG) on 8/17/2026.

Johnson & Johnson Price Performance

JNJ opened at $258.25 on Thursday. The company’s 50-day simple moving average is $265.71 and its two-hundred day simple moving average is $248.78. The company has a debt-to-equity ratio of 0.44, a quick ratio of 0.81 and a current ratio of 1.09. The stock has a market capitalization of $622.35 billion, a P/E ratio of 29.92, a P/E/G ratio of 2.50 and a beta of 0.21. Johnson & Johnson has a 52-week low of $184.66 and a 52-week high of $281.07.

Johnson & Johnson (NYSE:JNJ) last issued its earnings results on Wednesday, July 15th. The company reported $2.90 earnings per share (EPS) for the quarter, topping the consensus estimate of $2.84 by $0.06. Johnson & Johnson had a net margin of 21.48% and a return on equity of 32.42%. The company had revenue of $25.31 billion for the quarter, compared to analysts’ expectations of $25.06 billion. During the same quarter last year, the company posted $2.77 earnings per share. The firm’s quarterly revenue was up 6.6% on a year-over-year basis. Johnson & Johnson has set its FY 2026 guidance at 11.600-11.750 EPS. As a group, analysts predict that Johnson & Johnson will post 11.54 EPS for the current year.

Johnson & Johnson Dividend Announcement

The firm also recently announced a quarterly dividend, which was paid on Tuesday, September 8th. Shareholders of record on Tuesday, August 25th were given a $1.34 dividend. The ex-dividend date of this dividend was Tuesday, August 25th. This represents a $5.36 dividend on an annualized basis and a yield of 2.1%. Johnson & Johnson’s payout ratio is 62.11%.

Hedge Funds Weigh In On Johnson & Johnson

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in the company. Outlook Capital Management LLC purchased a new position in shares of Johnson & Johnson in the second quarter valued at $28,000. Matrix Trust Co raised its stake in Johnson & Johnson by 56.2% during the second quarter. Matrix Trust Co now owns 150 shares of the company’s stock valued at $38,000 after purchasing an additional 54 shares in the last quarter. Montgomery Financial Services LLC bought a new position in Johnson & Johnson during the second quarter valued at $43,000. Hyposwiss Advisors SA bought a new stake in shares of Johnson & Johnson in the 4th quarter worth about $42,000. Finally, Polaris Financial Partners purchased a new stake in shares of Johnson & Johnson during the 3rd quarter valued at about $56,000. 69.55% of the stock is owned by institutional investors.

Trending Headlines about Johnson & Johnson

Here are the key news stories impacting Johnson & Johnson this week:

• Positive Sentiment: Analyst support remains strong. Guggenheim reaffirmed its “Buy” rating and set a $287 price target, implying roughly 11% upside from the referenced price. RBC Capital also maintained its “Buy” rating. RBC Capital Keeps Their Buy Rating on Johnson & Johnson
• Positive Sentiment: Investors are increasingly viewing JNJ as a growth story. Recent coverage highlighted second-quarter revenue growth of 6.6%, adjusted EPS growth of 4.7% and an increase in full-year 2026 guidance. This contrasts with Pfizer, whose lower valuation reflects expectations for declining earnings, helping explain why JNJ commands a much higher earnings multiple. Johnson & Johnson Is Becoming a Growth Stock
• Positive Sentiment: Pipeline progress adds longer-term upside. JNJ’s Tecvayli-Talvey combination produced substantial reductions in progression and mortality risk in a Phase 3 multiple-myeloma study. Separately, two-year data for oral psoriasis treatment ICOTYDE showed durable skin clearance and consistent safety, supporting its commercial potential. 2026 Cancer Treatment Advances ICOTYDE Long-Term Psoriasis Data
• Neutral Sentiment: A pricing agreement may reduce an overhang before earnings. Coverage said a pricing pact has eased investor concerns ahead of the company’s next results, though the precise financial impact and durability of the agreement remain important items to monitor. Johnson & Johnson Pricing Pact Eases Overhang
• Negative Sentiment: Risks temper the bullish case. Analysts and investors continue to assess biosimilar competition, a slower MedTech recovery, the coming pharmaceutical patent cliff and ongoing talc litigation. JNJ’s premium valuation leaves less room for execution or earnings disappointments. Johnson & Johnson Dividend Royalty Status

Wall Street Analysts Forecast Growth

A number of research firms have recently issued reports on JNJ. Stifel Nicolaus set a $260.00 price target on Johnson & Johnson in a research note on Wednesday, July 15th. Johnson Rice reissued a “buy” rating on shares of Johnson & Johnson in a research report on Monday, August 3rd. Freedom Capital upgraded Johnson & Johnson from a “hold” rating to a “strong-buy” rating in a research note on Thursday, July 16th. The Goldman Sachs Group reaffirmed a “buy” rating and issued a $282.00 target price on shares of Johnson & Johnson in a report on Thursday, July 16th. Finally, JPMorgan Chase & Co. boosted their price target on Johnson & Johnson from $270.00 to $285.00 and gave the company a “neutral” rating in a report on Tuesday, September 29th. One equities research analyst has rated the stock with a Strong Buy rating, eighteen have given a Buy rating and six have assigned a Hold rating to the stock. According to data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and an average price target of $276.22.

Insider Buying and Selling

In other Johnson & Johnson news, EVP Vanessa Broadhurst sold 23,054 shares of the business’s stock in a transaction on Monday, July 20th. The shares were sold at an average price of $251.27, for a total transaction of $5,792,778.58. Following the transaction, the executive vice president owned 23,003 shares in the company, valued at $5,779,963.81. The trade was a 50.06% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available at this link. Also, EVP Elizabeth Forminard sold 15,918 shares of the stock in a transaction on Thursday, August 6th. The shares were sold at an average price of $257.00, for a total transaction of $4,090,926.00. Following the completion of the sale, the executive vice president directly owned 16,994 shares in the company, valued at approximately $4,367,458. This represents a 48.37% decrease in their position. The SEC filing for this sale provides additional information. Over the last ninety days, insiders sold 87,569 shares of company stock valued at $23,064,544. Insiders own 0.16% of the company’s stock.

About Representative Doggett

Lloyd Doggett (Democratic Party) is a member of the U.S. House, representing Texas’ 37th Congressional District. He assumed office on January 3, 2023. His current term ends on January 3, 2027.

Doggett (Democratic Party) is running for re-election to the U.S. House to represent Texas’ 37th Congressional District. He declared candidacy for the 2026 election.

Lloyd Doggett was born in Austin, Texas. Doggett graduated from Austin High School in 1964. He earned a B.A. from the University of Texas at Austin in 1967 and a J.D. from the University of Texas in 1970. Doggett’s career experience includes working as an adjunct professor with the University of Texas School of Law. In the 116th Congress, Doggett served on the House Ways & Means Committee, and he co-founded the House Prescription Drug Taskforce.

About Johnson & Johnson

Johnson & Johnson (NYSE: JNJ) is a global healthcare company that develops, manufactures and markets products through two primary business segments: Innovative Medicine and MedTech. Its operations serve patients, healthcare professionals and consumers in markets around the world.

The Innovative Medicine segment focuses on prescription medicines in areas including immunology, oncology, neuroscience, cardiovascular and metabolic disease, infectious diseases, and pulmonary hypertension.